The ICD-10 code for May Hegglin Anomaly is D72.1. This code is used to classify this rare genetic disorder characterized by abnormal platelets, large inclusion bodies in white blood cells, and mild bleeding tendencies. In the previous ICD-9 system, the code for May Hegglin Anomaly was 287.31. It is important to consult with a healthcare professional for accurate diagnosis and appropriate treatment.
May-Hegglin anomaly (MHA) is a rare genetic disorder characterized by abnormal platelets, giant platelets, and presence of Döhle-like bodies in white blood cells. The ICD-10 code for May-Hegglin anomaly is D69.4. This code falls under the category of "Other primary thrombocytopenia" in the ICD-10 coding system.
In the older ICD-9 coding system, May-Hegglin anomaly was not specifically classified. However, it could potentially be categorized under other related codes such as 287.31 (Thrombocytopenia, unspecified) or 289.84 (Other specified diseases of blood and blood-forming organs).
May-Hegglin anomaly is a rare condition, and its diagnosis is typically made through a combination of clinical presentation, blood tests, and microscopic examination of blood smears. Patients with MHA may experience symptoms such as easy bruising, nosebleeds, and prolonged bleeding after injury or surgery. In some cases, MHA may be associated with kidney problems or hearing impairment.
Treatment for May-Hegglin anomaly is usually focused on managing symptoms and preventing complications. This may include close monitoring of platelet counts, avoiding medications that can further affect platelet function, and taking precautions to minimize the risk of bleeding. In severe cases, platelet transfusions may be necessary.
It is important for individuals with May-Hegglin anomaly to work closely with their healthcare providers to develop an appropriate management plan tailored to their specific needs.